Sign in
TerminatedPhase 1

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Key facts

Who runs it
ModernaTX, Inc.
Where
Austin, Beaumont, Chattanooga, Chicago, Columbus, Houston, Lakeland, Lenexa, Longmont, Los Angeles, Medford, Miami, Miami Lakes, New Orleans, Philadelphia, River Forest, Sioux City, Tomball, and Winter Park, United StatesSee the 19 sitesAlso in 1 other country, 1 site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
659 people enrolled
Started
23 Jan 2023
Ended
31 Dec 2025
Type of study
Interventional, 8 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • mRNA-1468
  • Placebo
  • Shingrix
Record updated
5 August 2026
Why it stopped
The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further development of the vaccine.

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Part 1: Is an adult 50 years of age or older at the time of consent. Part 2: Is an adult 50-69 years of age at the time of consent
  • Has a body mass index of 18 to <40 kilograms/meter squared at the Screening Visit
  • Females of childbearing potential: have a negative pregnancy test at the Screening Visit and on the day of the first vaccination (Day 1); have practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1; have agreed to continue adequate contraception through 3 months following vaccine administration; are not currently breastfeeding

Who cannot take part

  • Has been previously vaccinated against varicella or HZ
  • Body temperature ≥38.0°Celsius/100.4°Fahrenheit 72 hours prior to or at the Screening Visit or on Day 1. Participants meeting this criterion may be rescheduled within the allowed window
  • Has a current or previous diagnosis of congenital or acquired immunodeficiency, immunocompromizing/immunosuppressive condition, asplenia, or recurrent severe infections. Certain immune-mediated conditions that are well controlled and stable (for example, Hashimoto thyroiditis) as well as those that do not require systemic immunosuppressive therapy (for example, asthma, psoriasis, or vitiligo) may be permitted at the discretion of the Investigator
  • Has received systemic immunosuppressants for >14 days in total within 180 days prior to Screening Visit (for corticosteroids ≥10 milligrams/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal, intra-articular and topical steroids are allowed
  • Has received systemic immunoglobulins, long-acting biological therapies that affect immune responses (for example, Infliximab) or blood products within 90 days prior to the Screening Visit or plans to receive them during the study; Other protocol-defined inclusion/exclusion criteria apply
  • Has a history of HZ within the past 10 years
  • Has a dermatologic condition that could affect local solicited adverse reaction assessments (for example, tattoos, psoriasis patches affecting skin over the deltoid areas)
  • Has any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results
  • Has a history of myocarditis, pericarditis, or myopericarditis
  • Has a reported history of anaphylaxis or severe hypersensitivity reaction after receipt of any mRNA vaccine(s) or any components of the mRNA vaccines
  • Is acutely ill or febrile

Where in United States

Also in 1 other country, 1 site

  • Tekton ResearchAustin, United States
  • Gadolin ResearchBeaumont, United States
  • WR-ClinSearch, LLCChattanooga, United States
  • Great LakesChicago, United States
  • Centricity ResearchColumbus, United States
  • LinQ Research, LLCHouston, United States
  • Meridien ResearchLakeland, United States
  • Johnson County Clin-Trials (JCCT)Lenexa, United States
  • Tekton Research, Inc - Longmont CenterLongmont, United States
  • Velocity Clinical Research, WestlakeLos Angeles, United States
  • Velocity Clinical Research, MedfordMedford, United States
  • Clinical Trials of Florida, LLCMiami, United States
  • Floridian Clinical ResearchMiami Lakes, United States
  • NOLA Research WorksNew Orleans, United States
  • DM Clinical Research - PhiladelphiaPhiladelphia, United States
  • DM Clinical Research - River ForestRiver Forest, United States
  • Meridian Clinical Research - Dakota DunesSioux City, United States
  • DM Clinical ResearchTomball, United States
  • Florida Pulmonary Research Institute, LLCWinter Park, United States

About the trial

What the trial wants to find out

The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.

The 8 groups in the trial

  • Part 1: mRNA-1468: Dose 1Treatment being tested

    Participants will receive placebo by intramuscular (IM) injection on Day 1 followed with mRNA-1468 by IM injection on Day 57 in Part 1.

    Treatment: mRNA-1468 and Placebo

  • Part 1: mRNA-1468: Dose 2Treatment being tested

    Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1.

    Treatment: mRNA-1468

  • Part 1: mRNA-1468: Dose 3Treatment being tested

    Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1.

    Treatment: mRNA-1468

  • Part 1: mRNA-1468: Dose 4Treatment being tested

    Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1.

    Treatment: mRNA-1468

  • Part 1: ShingrixExisting treatment, for comparison

    Participants will receive Shingrix by IM injection on Day 1 and Day 57 in Part 1.

    Treatment: Shingrix

  • Part 2: mRNA-1468: Dose 5Treatment being tested

    Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 2.

    Treatment: mRNA-1468

  • Part 2: mRNA-1468: Dose 6Treatment being tested

    Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 2.

    Treatment: mRNA-1468

  • Part 2: ShingrixExisting treatment, for comparison

    Participants will receive Shingrix by IM injection on Day 1 and Day 57 in Part 2.

    Treatment: Shingrix

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
Record updated
5 August 2026